amylin vs glp-1 Amycretin — a novel obesity treatment that targets both and receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD Combined Amylin/GLP-1 pharmacotherapy to promote

A component of the Gila monsters venoma peptide known as exendin-4is being explored for new treatments for Alzheimers disease, diabetes, and other diseases.

There are currently two major players with a decisive head start in the obesity drug space: Eli Lilly (LLY) and Novo Nordisk (NVO)

A dual GIP/GLP-1 agonist studied in metabolic research

The percentage of Americans taking GLP-1 drugs such as Ozempic or Zepbound to lose weight has nearly quadrupled since 2024, according to a new survey by Gallup

Twenty years years of teaching, and marking papers until midnight had become the norm

Prices are expected to further decline as KSMs continue to fall in price and competition intensifies For procurement teams and strategy leads, this means a dramatically different cost base and has major implications for development/CMO contracts and price forecasting